GB-7624
Anti-IL-13 therapeutic for atopic dermatitis, entering Phase 1 trial in early 2025.
Executive Summary
GB-7624 is an anti-IL-13 therapeutic developed by Generate Biomedicines, specifically designed to target atopic dermatitis, a chronic inflammatory skin condition. This therapeutic is a product of Generate Biomedicines' pioneering machine learning-powered multimodality generative biology platform. Generate Biomedicines leverages its advanced AI platform to design and optimize novel protein therapeutics. GB-7624 is currently preparing to enter a Phase 1 clinical trial in early 2025, marking a significant step in its development pipeline towards providing a new treatment option for patients with atopic dermatitis.
Use Cases
- Treating atopic dermatitis
- Developing novel anti-inflammatory therapeutics
- Advancing drug candidates through clinical trials
- Utilizing generative AI for drug discovery
Features
Intelligence
- Novel Protein Generation: Generates entirely new protein structures and sequences that have never existed, based on specified functional criteria.
- Programmable Protein Design: Allows for the design of proteins with specific geometric and functional properties using generative models like Chroma.
- Therapeutic Optimization: Optimizes existing protein therapeutics to improve efficacy, reduce immunogenicity, or enhance stability.
Technical Specifications
- Architecture
- Machine learning-driven generative biology platform
- Deployment
- SaaS
AI/ML Stack
- Generative AI
- Machine Learning
- Deep Learning
- Chroma (generative model)
- Generative Biology
- Generative Protein Design
About Generate Biomedicines
Generate Biomedicines is a therapeutics company pioneering generative biology at the intersection of machine learning, biological engineering, and medicine to create breakthrough medicines. It operates as a developer of a machine learning-powered biomedicines platform with the potential to generate new drugs across a wide range of biologic modalities.
Alternatives to GB-7624
- Geneious Biologics by Dotmatics — Accelerate antibody discovery with cloud-based screening, analysis, and visualization.
- Generate Platform by Generate Biomedicines — Pioneering generative biology to create breakthrough medicines with AI.
- Generative Biologics by Insilico Medicine — AI-powered platform for generative design and optimization of biologics.
- inClinico by Insilico Medicine — Generative AI-powered platform for data-driven, multimodal prediction of clinical trial outcomes.
- Insitro Platform by Insitro — Machine Learning to Unravel Biology and Redefine Disease for Better Drugs, Faster.
- iPSC-based disease modeling by Evotec — Leveraging iPSCs for advanced disease modeling in drug discovery.
- Isomorphic Labs Platform by Isomorphic Labs — Harnessing AI to unlock deeper scientific insights for life-changing medicines.
- Just - Evotec Biologics by Evotec — Accelerating biologics development and manufacturing with J.POD® continuous technology.